P. Ford (London, United Kingdom), G. Caramori (Ferrara, Italy)
A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004
T. Willis, K. Wee, G. Mohn (Raleigh, United States Of America)
|   |
The prophylactic effect of Nigella sativa seed on respiratory symptoms and pulmonary function tests of chemical war victims
M. H. Boskabady, J. Farhadi (Mashhad, Islamic Republic Of Iran)
| |
Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP)
N. Slepchenko, A. Sidorov, Y. Mostovoy (Vinnitsa, Ukraine)
| |
Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety
N. Roth, G. Buczynski, K. Cai, W. Osheroff, M. Burdick, J. Wang, H. Renfrow, M. Nelson, J. Hotta (Research Triangle Park, United States Of America)
| |
Efficacy of symbicort administration in patients with bronchial asthma
U. Farkhutdinov, R. Rachmatullina, S. Farkhutdinov, E. Achmadeeva (Ufa, Russian Federation)
| |
Patients‘ treatment effects with asthma under applying basic therapy combined with cardiocytoprotector mildronat
O. Yakovleva, A. Zhamba (Vinnitsa, Ukraine)
| |
Effect of sildenafil on exercise ability of patients with World Health Organization functional class II pulmonary arterial hypertension
N. Galie, H. Gillies, M. Oakes, G. Simonneau (Bologna, Italy; Sandwich, United Kingdom; Paris, France)
| |
Sequential nebulized salbutamol therapy in patients of acute bronchial asthma and its effect on serum potassium level
J. K. Samaria, S. C. Matah, M. P. Singh (Varanasi, India)
| |
A new tool for monitoring patient adherence with aerosol therapy using an eflow nebulizer system
M. Keller, W. Achtzehner, C. Fuchs, R. Pokorski, S. Seemann, M. Knoch (Munich, Germany)
| |
Cough suppresive and bronchodilatory activities of polysaccharides isolated from the malian medicinal plants
M. Sutovska, S. Franova, L. Prisenznakova, P. Capek (Martin, Bratislava, Slovakia)
| |
Respiratory function and airway inflammation in patients with hypothyroidism. The effect of treatment
S. Loukides, P. Lyberopoulos, M. Peppa, G. Papatheodorou, D. Hadjidakis, S. Papiris (Athens, Greece)
| |
Are the spacers different in terms of lung bioavailability of salbutamol? An observational comparative study
S. Baniasadi, F. Fahimi, J. Salamzadeh, F. Kobarfard, A. Fakharian, P. Abdollahi, M. R. Masjedi (Tehran, Islamic Republic Of Iran)
| |
Antalgic treatment and non neoplasic acute chest pain
L. Boussoffara, N. Boudawara, S. Darouaz, J. Knani (Mahdia, Tunisia)
| |
Drug deposition by cascade impactor of two dry powder inhalers
C. Ranasinha, A. Sudeera, J. Mangala, A. Goonathilake (Ragama, Moratuwa, Gangodawila, Sri Lanka)
| |
Factors associated with poor prognostic outcome in acute exacerbation of COPD
G. Gaude, B. P. Rajesh (Belgaum, India)
| |
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity
N. Abd Elaty (Ismailia, Egypt)
| |
Ambroxol for the prevention of acute upper respiratory disease
K. Nobata, H. Asanoi (Imizu, Japan)
| |
Adherence to high-frequency chest wall oscillation (HFCWO) improves quality of life in COPD
G. Diette, A. Bilderback, B. Becker, D. Kachel, R. Wise, C. Rand (Baltimore, St. Paul, Minneapolis, United States Of America)
| |
Features of short acting β-2-agonist (SABA) use in COPD early stages
A. Budnevsky, A. Lisova, I. Zolotaryev (Voronezh, Russian Federation)
| |
Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD
D. Bock, A. Wenker, B. Müllinger, D. Beyer, K. Schierhorn, W. Meyer-Sabellek (Hennigsdorf, Gemünden/Wohra, Germany)
| |